Empagliflozin Treatment Is Associated With Improvements in Cardiac Energetics and Function and Reductions in Myocardial Cellular Volume in Patients With Type 2 Diabetes

Empagliflozin Treatment Is Associated With Improvements in Cardiac Energetics and Function and Reductions in Myocardial Cellular Volume in Patients With Type 2 Diabetes

Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of major adverse cardiovascular (CV) events and hospitalization for heart failure (HF) in patients with type 2 diabetes (T2D). Using CV MRI (CMR) and 31P-MRS in a longitudinal cohort study, we aimed to investigate the effects of the s...

Full description

Saved in:
Bibliographic Details
Main Authors: Sharmaine Thirunavukarasu, Nicholas Jex, Amrit Chowdhary, Imtiaz Ul Hassan, Sam Straw, Thomas P. Craven, Miroslawa Gorecka, David A. Broadbent, Peter Swoboda, Klaus K. Witte, Richard M. Cubbon, Hui Xue, Peter Kellman, John P. Greenwood, Sven Plein, Eylem Levelt
Format: Artigo
Language:English
Published: 2021
Online Access:https://doi.org/10.2337/db21-0270
https://diabetesjournals.org/diabetes/article-pdf/70/12/2810/634595/db210270.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.2337/db21-0270
https://diabetesjournals.org/diabetes/article-pdf/70/12/2810/634595/db210270.pdf

Similar Items